CDKN2A and thymic carcinoma: Recurrent CDKN2A alterations in TETs, mainly due to chromosome 16q loss in thymic carcinoma, as well as the upregulation of MYC/Max and E2F1, lead to hyperactivation of the CDK4-6/Rb pathway and subsequent cell cycle impairment [5].